SURROZEN, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.98 USD | +4.30% |
|
-4.52% | -4.47% |
| 04-10 | Surrozen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 04-08 | Surrozen Insider Bought Shares Worth $2,999,994, According to a Recent SEC Filing | MT |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 28.72M 2.3B |
|---|---|---|---|---|---|
| Net income 2024 * | -27M -2.16B | Net income 2025 * | -43M -3.44B | EV / Sales 2024 * | - |
| Net cash position 2024 * | 19.3M 1.55B | Net cash position 2025 * | 85M 6.8B | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.23
x | P/E ratio 2025 * |
-1.64
x | Employees | 42 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.34% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +4.30% | ||
| 1 week | -4.52% | ||
| Current month | -42.84% | ||
| 1 month | -37.33% | ||
| 3 months | +18.16% | ||
| 6 months | +52.72% | ||
| Current year | -4.47% |
1 week
8.14
9.84
1 month
8.1414.96
Current year
7.1516.19
1 year
4.5016.19
3 years
4.50210.00
5 years
4.50210.00
10 years
4.50210.00
| Managers | Title | Age | Since |
|---|---|---|---|
Craig Parker
CEO | Chief Executive Officer | 63 | 28/02/18 |
Charles Williams
DFI | Director of Finance/CFO | 46 | 31/10/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Craig Parker
CEO | Chief Executive Officer | 63 | 28/02/18 |
Eric Bjerkholt
BRD | Director/Board Member | 64 | 04/04/23 |
Mace Rothenberg
BRD | Director/Board Member | 67 | 31/03/21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 8.98 | +4.30% | 11,126 |
| 25/04/24 | 8.61 | -4.01% | 5,086 |
| 24/04/24 | 8.97 | -0.44% | 8,980 |
| 23/04/24 | 9.01 | -2.59% | 2,309 |
| 22/04/24 | 9.25 | -1.65% | 9,310 |
Delayed Quote Nasdaq, April 26, 2024 at 09:30 pm
More quotes
Surrozen, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a range of organs and tissues. The Company's lead product candidates are multi-specific, antibody-based therapeutics that mimic the roles of naturally occurring Wnt or R-spondin proteins, which are involved in activation and enhancement of the Wnt pathway. Its two technologies, Surrozen Wnt signal Activating Protein (SWAP) and Surrozen Wnt signal Enhancers Engineered for Tissue Specificity (SWEETS), enable it to potently and selectively modulate Wnt signaling through the generation of Wnt and R-spondin mimetics. SWAP molecules are designed to mimic the activity of naturally occurring Wnt proteins. SWEETS molecules are designed to amplify the bodyâs response to naturally occurring Wnt proteins. Its product candidates include SZN-1326, SZN-043 and SZN-413.
Calendar
07/05/2024
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
8.98
USD
Average target price
33
USD
Spread / Average Target
+267.49%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.47% | 28.72M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- SRZN Stock
